Ionis have recently released a community statement to the AxD community regarding their zilganersen program and the recent partnership with Recordati:
“Ionis is pleased to inform you that we have entered into a partnership with Recordati to lead commercialization efforts for the investigational drug zilganersen in countries outside the U.S. Recordati will be responsible for regulatory filings in markets outside the U.S., including country-specific support for early access pathways, depending on local regulations and access dynamics.”
To read: Ionis Community Statement
